iCell® Hepatocytes 2.0
Investigate Liver Disease with Human Hepatocytes
The medical community needs a reproducible, well-characterized, and readily available source of human hepatocytes to advance significantly the launch of new metabolic and infectious disease therapies, reduce the incidence of drug-induced liver injury, and accelerate the development of novel approaches to liver regeneration and transplantation.
To meet this need, CDI has leveraged iPS cell technology to develop iCell® Hepatocytes. These hepatocytes overcome the functionality, reproducibility, and availability limitations of existing primary cell and tumor-derived cell models by providing the following:
- Relevant hepatic functionality and phenotypic stability
- Expression of clinical targets that are relevant for liver and metabolic disease
- Compatibility with a wide range of 3D and microphysiological systems
- Quality-controlled manufacturing and batch reproducibility
- Ready supply in a cryopreserved format
Two Types to Choose From
Cellular Dynamics offers 2 terminally differentiated hepatocyte products: iCell Hepatocytes and iCell Hepatocytes 2.0. While the original iCell Hepatocytes enable a shorter workflow in a more matured product at thaw, iCell Hepatocytes 2.0 do not require Matrigel in culture and have some functional advantages in vitro. Please inquire for additional guidance on the product that best meets your specific application.
|iCell Hepatocytes||iCell Hepatocytes 2.0|
|Albumin Expression||Upon thawing||After 5 days of culture|
|CYP activity||48 hours||7-10 days|
|Time to assay||24 hours post-thaw||7 days post-thaw|
|Viability in culture||14-21 days||21-28 days|
|Matrigel in Culture||Required||Not required|
iCell Hepatocytes 2.0 are being rapidly adopted for use in a wide range of applications:
- Diabetes research and drug discovery
Functional insulin and glucose regulation pathways and a flexible product format enable high-throughput screening for novel drug candidates.
- Infectious disease studies
Native human biology and long-term phenotypic stability support hepatitis viral replication including growth of clinically relevant genotypes (Ng et al., 2015; Mann et al., 2013; Schlomai et al., 2013; CDI Application Note).
- Hepatotoxicity assessment
Known genetic background and proven ability to detect metabolism-dependent and immune-mediated hepatotoxicity provide confidence in safety testing without the need for time-consuming and costly lot testing (Sirenko et al., 2013; Mann, 2014; Lu et al., 2015).
- Liver tissue engineering
Compatibility with bioengineered scaffold engraftment, organ recellularization, and 3D printing enable new clinical and regenerative medicine strategies (Berger et al., 2015; Ware et al., 2015).
- 3D spheroid culture
iCell Hepatocytes form stable, highly uniform spheroids in low attachment plates under a protocol developed at CDI enabling more in vivo-like three dimensional culture and applications.